engin
strain
mice
produc
human
instead
mous
antibodi
emerg
evolv
past
two
decad
us
regulatori
approv
panitumumab
fulli
human
antibodi
direct
epiderm
growth
factor
receptor
transgen
mice
express
human
antibodi
repertoir
join
chimer
cdr
graft
phage
display
technolog
commerci
valid
antibodi
drug
discoveri
platform
dozen
addit
transgen
mousederiv
human
mab
clinic
develop
new
drug
discoveri
platform
appear
firmli
establish
within
pharmaceut
industri
discoveri
hybridoma
method
isol
high
specif
high
affin
rodent
monoclon
antibodi
mab
open
door
new
class
therapeut
compound
potenti
applic
across
wide
rang
diseas
indic
kohler
milstein
promis
appear
fulfil
us
regulatori
approv
treatment
kidney
transplant
reject
goldstein
et
al
howev
despit
fact
act
potent
immunosuppress
drug
turn
intrins
immunogen
molecul
rodent
antibodi
foreign
protein
human
immun
system
mount
antibodi
respons
lead
rapid
clearanc
reduc
efficaci
goldstein
et
al
pendley
et
al
kuusreichel
et
al
increas
risk
infus
reaction
baert
et
al
potenti
solut
problem
immunogen
fulli
human
mab
time
appear
practic
limit
avail
target
specif
human
antibodi
larrick
bourla
jame
bell
houghton
olsson
et
al
although
larg
panel
rodent
mab
could
easili
assembl
screen
optim
bind
intend
target
low
crossreact
relat
molecul
analog
technolog
gener
isol
human
mab
full
rang
specif
affin
afford
rodent
hybridoma
method
exist
smaller
pool
avail
reactiv
human
antibodi
might
factor
select
earli
human
mab
clinic
candid
enter
clinic
test
treatment
sepsi
late
gain
european
regulatori
approv
brunbuisson
polyreact
authent
human
mab
bound
intend
target
lipid
rel
nonspecif
hydrophob
interact
heavi
chain
v
region
framework
residu
helmhorst
et
al
bieber
et
al
clinic
us
regulatori
failur
spald
edgington
mccloskey
et
al
togeth
observ
immunogen
contribut
consider
cool
enthusiasm
antibodybas
drug
within
pharmaceut
industri
howev
year
approv
second
mabbas
drug
engin
chimer
antibodi
fragment
abciximab
simoon
et
al
gain
approv
follow
approv
addit
mabbas
drug
last
year
class
drug
compound
mab
appear
rescu
use
technolog
reengin
rodent
antibodi
vitro
replac
framework
amino
acid
residu
correspond
human
sequenc
morrison
et
al
jone
et
al
addit
technolog
also
develop
directli
isol
synthet
mab
librari
human
synthet
immunoglobulin
sequenc
mccafferti
although
exist
antibodi
engin
technolog
appear
success
gener
therapeut
product
accept
safeti
efficaci
may
still
room
improv
although
product
gener
antibodi
engin
elicit
patient
immun
respons
approv
mab
product
includ
exampl
chimer
cdr
graft
phage
display
found
immunogen
pendley
et
al
evolut
therapeut
antibodi
technolog
progress
clinic
fdaapprov
mab
emerg
year
date
new
technolog
base
report
scientif
literatur
morrison
et
al
jone
et
al
mccafferti
et
al
kohler
milstein
lonberg
et
al
green
et
al
transgen
mous
strain
compris
human
immunoglobulin
repertoir
repres
altern
platform
technolog
discov
low
immunogen
therapeut
mab
fig
contrast
antibodi
engin
technolog
involv
downstream
modif
optim
individu
protein
molecul
transgen
technolog
use
upstream
genet
engin
strain
mice
use
drug
discoveri
tool
directli
gener
human
sequenc
antibodi
move
clinic
without
optim
twelv
year
appear
scientif
literatur
lonberg
et
al
green
et
al
immunoglobulin
transgen
mice
valid
drug
discoveri
platform
regulatori
approv
first
product
panitumumab
gibson
et
al
review
discuss
develop
technolog
drug
deriv
fundament
basic
research
mous
embryolog
molecular
biolog
larg
number
laboratori
nagi
et
al
led
develop
earli
set
tool
manipul
mous
genom
fig
gener
genet
engin
mice
direct
microinject
clone
dna
sequenc
pronuclei
singlecel
halfday
embryo
report
sever
group
gordon
ruddl
costantini
laci
brinster
et
al
harber
et
al
wagner
et
al
wagner
et
al
microinject
dna
construct
insert
mous
chromosom
propag
germlin
could
includ
transcript
regulatori
sequenc
direct
express
restrict
differenti
cell
type
includ
b
cell
express
antibodi
gene
brinster
et
al
first
report
express
immunoglobulin
gene
transgen
mice
involv
small
transgen
howev
despit
fact
fine
glass
needl
employ
pronuclear
microinject
sheer
forc
experienc
inject
dna
prevent
use
techniqu
introduc
much
larger
kb
transgen
mous
germlin
costantini
laci
taylor
et
al
schedl
et
al
lonberg
huszar
fishwild
et
al
microinject
transgen
integr
rel
randomli
larg
number
potenti
site
within
mous
genom
provid
easi
manipul
specif
endogen
mous
gene
microinject
could
gener
mice
blastocyst
stage
embryo
grown
cultur
genet
modifi
reintroduc
develop
blastocyst
insert
glass
pipet
blastocoel
caviti
sitespecif
modif
es
cell
genom
engin
homolog
recombin
follow
select
screen
specif
recombin
cultur
e
larg
dna
fragment
insert
es
cell
chromosom
transfect
yeastbacteri
cell
fusion
f
entir
chromosom
chromosom
fragment
replic
without
integr
endogen
mous
chromosom
introduc
es
cell
microcellmedi
chromosom
transfer
mmct
g
short
ca
month
gener
time
mous
allow
rapid
crossbreed
combin
multipl
independ
genet
modif
singl
anim
express
human
gene
mous
ortholog
typic
still
activ
technic
hurdl
overcom
develop
positiveneg
select
vector
allow
select
screen
specif
target
homolog
recombin
event
cultur
cell
parallel
develop
embryon
stem
es
cell
line
could
cultur
manipul
vitro
reintroduc
old
blastocyst
stage
embryo
popul
germlin
result
chimer
mice
combin
two
technolog
led
gener
strain
engin
mice
compris
specif
target
modif
germlin
mansour
et
al
zijlstra
et
al
schwartzberg
et
al
commonli
introduc
specif
modif
lead
inactiv
endogen
gene
creation
commonli
refer
gene
knockout
mous
strain
gene
knockout
technolog
prove
enorm
valu
basic
research
appli
endogen
mous
immunoglobulin
loci
import
develop
transgen
mous
platform
human
antibodi
drug
discoveri
addit
applic
modifi
endogen
mous
gene
es
cell
also
prove
use
altern
pronuclear
microinject
introduct
larg
dna
clone
yac
clone
strauss
et
al
choi
et
al
jakobovit
et
al
davi
et
al
larg
human
chromosom
fragment
also
introduc
mous
germlin
use
es
cell
technolog
approach
call
microcellmedi
chromosom
transfer
mmct
human
fibroblastderiv
microcel
fuse
mous
es
cell
result
pluripot
cell
line
singl
human
chromosom
chromosom
fragment
includ
centromer
telomer
replic
assort
cell
divis
without
insert
endogen
mous
chromosom
tomizuka
et
al
quickli
recogn
new
tool
develop
manipul
mous
germlin
might
practic
appli
toward
gener
human
immunoglobulin
express
transgen
mice
alt
et
al
suggest
transgen
technolog
could
use
gener
new
human
sequenc
mab
start
unrearrang
germlineconfigur
transgen
author
conclud
although
conceptu
outlandish
might
realiz
nottoodist
futur
year
later
yamamura
et
al
report
cell
type
specif
express
human
immunoglobulin
gamma
heavi
chain
transgen
follow
report
express
rearrang
germlin
configur
unrearrang
chicken
rabbit
light
chain
transgen
transgen
mice
bucchini
et
al
goodhardt
et
al
mileston
recogn
time
contribut
toward
develop
transgen
platform
discov
human
mab
buttin
comment
recent
progress
field
invit
us
believ
creation
transgen
mice
b
cell
secret
wide
spectrum
human
antibodi
longer
reach
bruggemann
et
al
report
express
repertoir
human
igm
heavi
chain
gener
transgeneencod
immun
respons
mice
three
year
later
taylor
et
al
report
mice
compris
germlin
configur
human
heavyand
lightchain
transgen
produc
repertoir
human
igm
igg
antibodi
group
show
later
paper
igg
antibodi
product
class
switch
compris
somat
mutat
consist
function
affin
matur
report
mani
other
number
differ
laboratori
demonstr
human
gene
sequenc
could
direct
cell
type
specif
express
human
immunoglobulin
mice
exogen
gene
sequenc
could
undergo
normal
rearrang
modif
requir
gener
primari
secondari
antibodi
repertoir
howev
human
immunoglobulin
transgen
mice
intact
function
endogen
immunoglobulin
loci
also
express
mous
antibodi
chimer
mousehuman
antibodi
creation
use
platform
human
antibodi
drug
discoveri
mous
disrupt
endogen
immunoglobulin
loci
requir
combin
method
introduc
human
immunoglobulin
transgen
method
describ
earlier
gener
gene
knockout
mice
two
articl
one
laboratori
lonberg
et
al
green
et
al
report
gener
mice
four
differ
germlin
modif
two
target
disrupt
endogen
mous
heavyand
lightchain
gene
two
introduc
human
transgen
encod
heavi
chain
light
chain
although
articl
report
use
homolog
recombin
mous
es
cell
engin
similar
disrupt
endogen
mous
loci
differ
technolog
use
construct
deliv
human
sequenc
transgen
lonberg
et
al
use
pronuclear
microinject
introduc
reconstruct
minilocu
transgen
heavi
chain
contain
heavychain
variabl
v
h
divers
heavychain
join
j
h
region
togeth
constantregion
gene
segment
transgen
strain
construct
underw
vdj
join
togeth
somat
mutat
correl
class
switch
lightchain
transgen
includ
four
five
constant
region
contrast
green
et
al
use
fusion
yeast
protoplast
deliv
yeast
artifici
chromosom
yac
base
minilocu
transgen
case
heavi
chain
includ
v
h
j
h
gene
segment
togeth
constantregion
gene
segment
construct
underw
vdj
join
express
igm
igd
lightchain
yac
construct
includ
two
function
five
segment
togeth
neither
group
inactiv
endogen
locu
typic
laboratori
mous
strain
contribut
b
cell
repertoir
function
express
lead
subpopul
b
cell
produc
hybrid
b
cell
receptor
secret
antibodi
human
heavyand
mous
chain
howev
presenc
subpopul
prevent
isol
hybridoma
cell
line
secret
fulli
human
monoclon
igm
green
et
al
igg
lonberg
et
al
mab
recogn
target
antigen
mice
immun
abil
engin
mous
strain
compris
fraction
natur
human
primari
v
gene
segment
repertoir
gener
antibodi
varieti
target
may
reflect
rel
import
combinatori
divers
encod
germlin
librari
v
j
gene
segment
junction
somat
divers
product
assembl
matur
antibodi
gene
although
naiv
b
cell
sequenc
complet
encod
germ
line
junction
divers
intact
minilocu
transgen
creat
much
heavychain
repertoir
sequenc
appear
critic
antigen
recognit
unmut
b
cell
receptor
may
larg
respons
primari
repertoir
ignatovitch
et
al
davi
tomlinson
et
al
primari
repertoir
b
cell
low
affin
immunogen
enter
cellmedi
process
affin
matur
shown
gener
highaffin
antibodi
limit
vgene
repertoir
extrem
exampl
offer
report
engin
mous
strain
singl
function
human
v
h
gene
three
mous
gene
xu
davi
anim
demonstr
specif
antibodi
respons
varieti
tdepend
antigen
high
affin
somat
mutat
mab
character
includ
high
pm
affin
mab
hen
eggwhit
lysozym
howev
minim
vrepertoir
mice
respond
tindepend
antigen
dextran
author
suggest
respons
carbohydr
antigen
might
drive
evolutionari
select
larg
primari
repertoir
germlineencod
recognit
antigen
may
import
develop
rapid
primari
protect
respons
pathogen
featur
would
select
wild
less
import
isol
highaffin
antibodi
laboratori
mice
use
hyperimmun
protocol
trigger
celldepend
affin
matur
addit
affect
respons
tindepend
antigen
kinet
overal
immun
reaction
repertoir
size
may
impact
b
cell
develop
size
differ
b
cell
compart
fishwild
et
al
compar
mice
differ
number
lightchain
v
gene
segment
found
introduct
larger
repertoir
encod
lightchain
yac
clone
compris
approxim
half
repertoir
led
increas
popul
peripher
bone
marrow
b
cell
compart
rel
transgen
strain
compris
four
gene
rel
number
matur
immatur
b
cell
compart
also
appear
normal
mice
larger
v
gene
repertoir
mendez
et
al
gener
transgen
mice
nearli
complet
heavychain
v
repertoir
approxim
half
v
repertoir
compar
minilocu
mice
green
et
al
paper
later
analysi
mous
strain
green
jakobovit
show
vregion
repertoir
size
profound
effect
multipl
checkpoint
b
cell
develop
larger
repertoir
capabl
restor
b
cell
compart
near
normal
level
despit
fact
human
immunoglobulin
transgen
mice
express
b
cell
receptor
essenti
hybrid
mous
human
compon
eg
human
immunoglobulin
mous
signal
molecul
b
cell
develop
matur
appear
normal
b
cell
subtyp
furthermor
immunoglobulin
transgen
undergo
v
j
join
random
nucleotid
nregion
addit
class
switch
somat
mutat
gener
highaffin
mab
varieti
differ
antigen
process
affin
matur
anim
even
recapitul
normal
pattern
somat
mutat
hotspot
observ
authent
human
secondari
repertoir
antibodi
hard
lonberg
human
immunoglobulin
sequenc
introduc
germ
line
mice
compris
endogen
ig
heavychain
gene
inactiv
germlin
configur
human
immunoglobulin
chain
chain
heavi
chain
depict
bar
repres
sequenc
use
assembl
transgen
introduc
strain
mice
use
gener
isol
human
sequenc
mab
b
ishida
et
al
c
nicholson
et
al
mendez
et
al
e
fishwild
et
al
f
green
et
al
g
lonberg
et
al
h
zou
et
al
multipl
report
literatur
transgen
mice
immunoglobulin
repertoir
compris
human
heavyand
lightchain
sequenc
background
disrupt
endogen
heavyand
loci
fig
sever
differ
technolog
includ
pronuclear
microinject
yeast
protoplast
fusion
es
cell
employ
engin
mous
strain
introduct
largest
fraction
human
germlin
repertoir
facilit
microcellmedi
chromosom
transfer
use
techniqu
tomizuka
et
al
gener
es
cell
line
chimer
mice
contain
fragment
human
chromosom
includ
human
heavychain
loci
respect
addit
gener
chimer
mice
incorpor
appar
intact
human
chromosom
compris
light
chain
locu
germlin
transmiss
obtain
human
es
cell
line
subsequ
report
germlin
transmiss
obtain
human
heavychain
es
cell
line
mice
creat
express
complet
human
heavyand
lightchain
repertoir
genet
background
includ
disrupt
mous
heavyand
loci
complet
human
highaffin
nanomolar
mab
isol
anim
although
chromosom
fragment
could
transmit
germ
line
chaincontain
fragment
found
less
mitot
stabl
observ
stabil
heavi
chaincontain
fragment
may
deriv
fortuit
locat
immunoglobulin
heavychain
locu
igh
telomer
long
arm
human
chromosom
structur
chromosom
random
delet
igh
centromer
remov
nonimmunoglobulin
gene
leav
igh
centromer
telomer
function
intact
result
fragment
minim
crossspeci
trisomi
would
presum
select
cell
divis
observ
stabil
fragment
exploit
creat
artifici
construct
human
chromosom
fragment
includ
entir
human
heavychain
locu
togeth
entir
human
locu
kuroiwa
et
al
bruggemann
colleagu
also
gener
human
locu
transgen
use
creat
transgen
mice
express
partial
repertoir
three
human
immunoglobulin
loci
background
disrupt
endogen
heavychain
loci
nicholson
et
al
anoth
transgen
mous
platform
gener
chimer
antibodi
rather
fulli
human
sequenc
antibodi
develop
rajewski
colleagu
zou
et
al
mice
compris
rel
precis
replac
mous
constantregion
gene
segment
correspond
human
gene
sequenc
constantregion
gene
segment
replac
use
homolog
recombin
mous
es
cell
gene
secret
exon
replac
engin
accomplish
two
step
use
creloxp
recombin
system
also
mous
es
cell
scientif
literatur
includ
larg
number
report
describ
characterist
human
mab
deriv
transgen
mous
platform
review
literatur
provid
assess
function
platform
lonberg
divers
set
antigen
success
target
transgen
deriv
mab
includ
small
molecul
ball
et
al
farr
et
al
pathogenencod
protein
tzipori
et
al
mukherje
et
al
mukherje
et
al
et
al
greenough
et
al
sheoran
et
al
babcock
et
al
coughlin
et
al
vital
et
al
polysaccharid
antigen
chang
et
al
maitta
humansecret
protein
mendez
et
al
ishida
et
al
villadsen
et
al
bekker
et
al
yang
et
al
huang
et
al
mian
et
al
ostendorf
et
al
suarez
et
al
parri
et
al
rathanaswami
et
al
burgess
et
al
melnikova
bare
cellsurfac
protein
fishwild
et
al
mendez
et
al
fishwild
et
al
yang
et
al
yang
et
al
holm
borchmann
et
al
skov
et
al
teel
et
al
schuler
et
al
rowinski
et
al
heuck
et
al
ramakrishna
et
al
keler
et
al
bleeker
et
al
suzuki
et
al
imakiir
et
al
mori
et
al
garamboi
et
al
trikha
et
al
tai
et
al
boll
et
al
cohen
et
al
kuroki
et
al
sanderson
et
al
tse
et
al
van
royenkerkhoff
et
al
wang
et
al
et
al
melnikova
bare
teel
et
al
wu
et
al
villadsen
et
al
human
tumorassoci
glycosyl
variant
nozawa
et
al
transgen
mousederiv
mab
bind
affin
nm
rang
affin
rang
typic
seen
mab
deriv
wildtyp
mice
ball
et
al
yang
et
al
yang
et
al
keler
et
al
cohen
et
al
burgess
et
al
rang
probabl
function
natur
constraint
affin
matur
oper
vivo
foot
eisen
roost
et
al
howev
also
exampl
transgenicderiv
human
mab
picomolar
even
subpicomolar
affin
villadsen
et
al
describ
pm
affin
antibodi
wang
et
al
describ
pm
affin
mab
insulinlik
growth
factor
receptor
rathanaswami
et
al
report
sever
mab
pm
rang
one
mab
measur
affin
pm
rang
regulatori
approv
us
panitumumab
signific
mileston
transgen
mousederiv
mab
mark
first
commerci
valid
immunoglobulin
transgen
mous
drug
discoveri
platform
panitumumab
bind
epiderm
growth
factor
receptor
egfr
high
affin
k
block
ligand
bind
rowinski
et
al
yang
et
al
yang
et
al
foon
et
al
preclin
mous
xenograft
model
found
potent
lower
affin
mous
antibodi
yang
et
al
parent
alreadi
market
mousehuman
chimer
antiegfr
antibodi
cetuximab
cunningham
et
al
direct
comparison
safeti
efficaci
cetuximab
panitumumab
sidebysid
clinic
studi
addit
fact
cetuximab
antibodi
panitumumab
antibodi
complic
attempt
compar
two
drug
howev
initi
survey
avail
literatur
suggest
fact
panitumumab
fulli
human
antibodi
deriv
transgen
mous
may
differenti
chimer
cetuximab
cohenuram
saif
earli
phase
ii
trial
panitumumab
associ
higher
frequenc
skin
rash
cetuximab
howev
skin
rash
relat
mechan
action
egfrtarget
drug
includ
small
molecul
case
product
drug
immunogen
posit
correl
activ
cetuximab
calvo
rowinski
renal
cell
carcinoma
trial
involv
rel
small
number
patient
skin
rash
correl
longer
cancer
progressionfre
surviv
panitumumab
rowinski
et
al
later
trial
appear
indic
two
molecul
similar
clinic
activ
random
patient
treatment
arm
phase
iii
trial
line
chemotherapi
refractori
egfr
metastat
colorect
carcinoma
patient
gibson
et
al
object
respons
rate
patient
stabl
diseas
compar
respons
rate
stabl
diseas
control
cohort
compar
clinic
respons
seen
cetuximab
monotherapi
patient
phase
ii
trial
similar
set
refractori
egfr
metastat
colorect
carcinoma
patient
lenz
et
al
approxim
cetuximabtr
patient
classifi
object
respond
stabl
diseas
panitumumab
dose
mg
kg
everi
week
chimer
cetuximab
first
given
roughli
higher
load
dose
mg
follow
similar
weekli
dose
mg
lower
dose
schedul
select
panitumumab
reflect
longer
clearanc
time
fulli
human
antibodi
howev
termin
half
life
day
still
shorter
typic
found
igg
molecul
presum
due
larg
antigen
sink
provid
normal
tissu
express
egfr
gibson
et
al
report
patient
detect
level
antipanitumumab
antibodi
treatment
patient
lowgrad
infus
reaction
none
grade
reaction
contrast
cetuximab
patient
experienc
hypersensit
reaction
grade
reaction
despit
fact
patient
pretreat
antihistamin
prevent
infus
reaction
lenz
et
al
also
report
cetuximabtr
patient
develop
human
antichimer
antibodi
panitumumab
human
antibodi
antibodi
poor
mediat
fc
depend
cell
kill
activ
drug
may
function
nonfc
mediat
mechan
could
involv
blockad
ligandinduc
receptor
signal
andor
alter
signal
direct
mab
bind
consist
observ
mab
activ
mous
xenograft
model
sibl
human
antibodi
block
ligand
bind
activ
yang
et
al
howev
although
molecul
show
signific
bind
human
riii
bind
common
variant
riia
parren
et
al
variant
also
associ
clinic
respons
rituximab
weng
levi
therefor
formal
possibl
human
patient
activ
panitumumab
mediat
riia
individu
gibson
et
al
report
data
riia
allotyp
patient
respond
panitumumab
howev
posit
correl
allotyp
clinic
respons
found
might
indic
activ
mab
fc
mediat
potent
mediat
fcdepend
activ
might
follow
human
variant
panitumumab
could
improv
activ
theori
could
test
near
futur
clinic
data
becom
avail
second
egfr
bind
mab
zalutumumab
deriv
transgen
mice
bleeker
et
al
lammert
et
al
zalutumumab
phase
test
treatment
egfrposit
squamou
cell
cancer
head
neck
preclin
studi
show
like
panitumumab
also
potent
mous
xenograft
model
bleeker
et
al
howev
unlik
panitumumab
antibodi
may
function
elicit
fcmediat
effector
cell
activ
addit
block
ligand
bind
normal
receptor
function
comparison
clinic
activ
two
molecul
may
provid
insight
role
fcreceptor
interact
efficaci
safeti
drug
least
eight
transgen
mousederiv
human
mab
phase
clinic
trial
tabl
includ
zalutumumab
egfr
bind
mab
discuss
earlier
two
differ
antibodi
direct
one
direct
treatment
cancer
two
neutral
mab
direct
common
subunit
inflammatori
indic
antibodi
direct
rankl
bone
loss
denosomab
antibodi
direct
rankl
tnf
famili
member
stimul
matur
activ
osteoclast
mediat
bone
resorpt
drug
phase
clinic
trial
treatment
bone
loss
postmenopaus
women
cancer
patient
treatment
induc
bone
loss
skelet
diseas
caus
bone
metastas
singl
subcutan
dose
escal
phase
studi
osteoporot
patient
show
dosedepend
sustain
activ
month
block
bone
resorpt
report
seriou
drugrel
advers
event
bekker
et
al
denosomab
found
dosedepend
pharmacokinet
pk
termin
half
life
day
highest
mg
kg
dose
second
singl
dose
trial
patient
multipl
myeloma
bone
metastas
breast
cancer
show
decreas
bone
metabol
persist
studi
followup
period
mean
half
life
day
singl
mg
kg
dose
bodi
et
al
studi
measur
bone
metabol
use
urin
concentr
peptid
product
collagen
catabol
indirect
measur
anoth
trial
postmenopaus
women
look
repeat
dose
also
directli
measur
bone
densiti
mcclung
et
al
consist
reduct
bone
metabol
seen
singl
dose
studi
bone
densiti
found
increas
month
studi
even
patient
given
mg
drug
everi
month
advers
event
profil
treatment
group
significantli
differ
placebo
group
treat
patient
show
transient
level
antidenosomab
antibodi
singl
blood
sampl
confirm
later
blood
sampl
low
incid
measur
antidrug
antibodi
safeti
profil
long
halflif
sustain
drug
activ
consist
antibodi
rel
nonimmunogen
infrequ
dose
may
import
patient
complianc
parenter
deliv
proteinbas
therapeut
direct
chronic
indic
osteoporosi
low
immunogen
could
critic
featur
success
product
two
transgen
mousederiv
human
antibodi
direct
ipilimumab
also
appear
elicit
strong
patient
antidrug
antibodi
respons
despit
fact
mechan
action
drug
result
potent
upmodul
patient
immun
respons
neg
cell
signal
molecul
bind
two
ligand
also
recogn
posit
cell
signal
molecul
korman
et
al
ipilimumab
keler
et
al
human
antibodi
riba
et
al
antibodi
molecul
bind
human
block
ligand
bind
antagon
signal
result
activ
certain
cell
respons
experi
hamster
mab
block
mous
show
result
enhanc
immun
respons
mediat
tumor
reject
syngen
mous
tumor
model
leach
et
al
preclin
experi
cynomolgu
monkey
model
demonstr
ipilimumab
could
stimul
humor
immun
respons
coadminist
vaccin
keler
et
al
clinic
data
cancer
patient
report
ipilimumab
phan
et
al
hodi
et
al
riba
et
al
attia
et
al
blansfield
et
al
maker
et
al
sanderson
et
al
beck
et
al
thompson
et
al
riba
et
al
reuben
et
al
object
durabl
antitumor
respons
observ
drug
rosenberg
colleagu
conduct
trial
patient
metastat
melanoma
treat
ipilimumab
mg
kg
everi
week
six
cycl
given
load
dose
ipilimumab
mg
kg
follow
mg
kg
everi
week
six
cycl
patient
administ
subcutan
peptid
vaccin
overal
object
respons
rate
patient
combin
cohort
ongo
complet
partial
respons
report
month
followup
paper
group
includ
addit
metastat
melanoma
patient
treat
without
vaccin
receiv
ipilimumab
dose
high
mg
kg
togeth
renal
cell
carcinoma
patient
treat
ipilimumab
mg
kg
beck
et
al
overal
object
respons
rate
patient
report
group
also
combin
ipilimumab
high
dose
metastat
melanoma
patient
report
object
respons
rate
patient
administ
ipilimumab
mg
kg
phase
singl
dose
monotherapi
dose
escal
trial
metastat
melanoma
patient
receiv
dose
high
mg
kg
author
report
object
respons
rate
riba
et
al
although
one
four
respond
also
receiv
ipilimumab
riba
et
al
seriou
advers
event
report
ipilimumab
compris
spectrum
immunerel
inflammatori
respons
includ
rash
enterocol
hypophys
jaber
et
al
blansfield
et
al
riba
et
al
beck
et
al
howev
mechan
action
block
mab
involv
activ
immun
respons
consid
targetrel
toxic
fact
correl
clinic
respons
beck
et
al
reuben
et
al
beck
et
al
report
object
respons
rate
melanoma
renal
cell
cancer
patient
enterocol
respons
rate
patient
without
enterocol
inflammatori
advers
event
report
respond
medic
manag
may
includ
corticosteroid
interestingli
corticosteroid
treatment
appear
abrog
object
tumor
respons
beck
et
al
despit
observ
upregul
immun
respons
patient
treat
two
mab
drug
appear
readili
recogn
clear
human
immun
system
termin
halflif
day
report
riba
postdos
serum
trough
level
ml
ipilimumab
report
month
repeat
monthli
dose
mg
kg
sanderson
et
al
sanderson
et
al
also
report
repeatedli
dose
patient
develop
measur
antibodi
respons
ipilimumab
data
consist
data
preclin
studi
show
evid
monkey
antihuman
antibodi
format
cynomolgu
macaqu
dose
five
time
day
keler
et
al
despit
fact
mab
upregul
monkey
humor
immun
respons
coadminist
vaccin
sign
immun
clearanc
monkey
antihuman
antibodi
drug
titer
never
fall
ml
cours
studi
anoth
transgenicderiv
human
mab
phase
develop
cnto
direct
common
subunit
share
result
report
phase
trial
multipl
sclerosi
kasper
et
al
phase
trial
psoriasi
kauffman
et
al
toichi
et
al
krueger
et
al
phase
psoriasi
trial
drug
show
sustain
activ
week
followup
singl
iv
administr
patient
achiev
least
improv
assess
psoriasi
area
sever
index
treatmentrel
seriou
advers
event
infus
reaction
antidrug
antibodi
detect
patient
howev
presenc
drug
serum
long
termin
half
life
day
preclud
accur
assess
patient
similar
day
termin
halflif
observ
multipl
sclerosi
trial
drug
given
subcutan
administr
one
treat
patient
develop
detect
antidrug
respons
howev
psoriasi
trial
persist
drug
serum
made
difficult
accur
measur
antidrug
antibodi
phase
psoriasi
trial
patient
receiv
drug
four
weekli
mg
subcutan
dose
antidrug
antibodi
detect
week
monitor
treat
patient
howev
measur
antibodi
respons
correl
inject
site
reaction
occur
frequenc
placebo
drugtreat
cohort
patient
given
singl
subcutan
dose
either
mg
show
sustain
diseasemodifi
respons
month
follow
treatment
togeth
observ
sustain
clinic
benefit
approxim
day
termin
halflif
cnto
appear
indic
elicit
strong
drugclear
antibodi
respons
clinic
data
report
interest
compar
immunogen
pk
safeti
efficaci
transgen
mousederiv
cnto
phage
display
deriv
also
direct
common
subunit
mannon
et
al
fuss
et
al
phage
display
antibodi
also
show
sign
immunogen
antidrug
antibodi
detect
patient
patient
show
evid
earli
clearanc
drug
serum
mannon
et
al
howev
patient
receiv
weekli
dose
drug
difficult
compar
data
report
cnto
termin
half
life
report
data
also
soon
avail
compar
second
pair
antibodi
direct
share
target
deriv
compet
transgen
mous
phage
display
technolog
platform
golimumab
human
sequenc
antibodi
transgen
mice
phase
clinic
test
rheumatoid
arthriti
adalimumab
phage
display
deriv
antibodi
current
approv
indic
high
affin
block
mab
weinblatt
et
al
also
molecul
formul
subcutan
administr
comparison
may
particular
interest
adalimumab
report
elicit
antidrug
antibodi
high
frequenc
despit
fact
genet
engin
lead
molecul
origin
isol
phage
display
librari
construct
human
immunoglobulin
sequenc
format
antidrug
antibodi
correl
advers
event
reduc
efficaci
studi
rheumatoid
arthriti
patient
bender
et
al
anoth
approv
block
antibodi
infliximab
chimer
mousehuman
antibodi
also
elicit
strong
antidrug
antibodi
respons
correl
infus
reaction
reduc
efficaci
baert
et
al
data
third
mab
deriv
altern
technolog
may
provid
insight
rel
import
factor
drug
target
patient
popul
intrins
immunogen
efficaci
safeti
antibodybas
therapeut
zanolimumab
transgen
mousederiv
human
antibodi
direct
cell
antigen
fishwild
et
al
result
patient
placebocontrol
phase
trial
psoriasi
report
skov
et
al
drug
phase
clinic
test
cutan
cell
lymphoma
publish
psoriasi
studi
observ
dosedepend
decreas
circul
cell
particularli
memori
cell
popul
may
translat
efficaci
cancer
set
drug
current
develop
villadsen
et
al
drug
well
toler
one
like
drugrel
seriou
advers
event
rash
appear
second
dose
mg
patient
develop
antidrug
antibodi
publish
preclin
studi
fishwild
et
al
antibodi
found
nonimmunogen
chimpanze
howev
induc
block
antibodi
respons
major
dose
cynomolgu
monkey
demonstr
primat
model
may
case
overestim
immunogen
ofatumumab
teel
et
al
transgen
mousederiv
antibodi
direct
b
cell
surfac
antigen
also
phase
clinic
develop
although
antibodi
share
target
mousehuman
chimer
mab
rituximab
current
approv
treatment
nonhodgkin
lymphoma
nhl
rheumatoid
arthriti
coiffier
et
al
recogn
distinct
epitop
may
result
differ
mechan
action
teel
et
al
rituximab
appear
recogn
one
two
extracellular
loop
ofatumumab
epitop
compris
residu
loop
antibodi
potent
mediat
complementdepend
cytotox
vitro
rituximab
differ
potenc
pronounc
lower
antigen
densiti
may
translat
greater
activ
low
express
lymphoma
chronic
lymphocyt
leukemia
cll
drug
current
test
phase
clinic
trial
potenti
differ
mechan
action
activ
ofatumumab
rituximab
comparison
rel
safeti
efficaci
profil
may
use
evalu
potenti
human
vs
chimer
antibodi
howev
process
select
ofatumumab
lead
clinic
candid
teel
et
al
teel
et
al
highlight
import
advantag
transgen
mous
platform
antibodi
drug
discoveri
platform
unlik
antibodi
engin
technolog
make
low
immunogen
mab
earli
lead
candid
modifi
optim
vitro
reduc
immunogen
transgen
mous
platform
process
lead
optim
bypass
make
possibl
test
potenti
lead
candid
seri
increasingli
sophist
vitro
vivo
assay
essenti
molecular
form
eventu
use
human
resourc
would
otherwis
devot
optim
small
number
lead
hit
devot
better
character
larger
number
lead
candid
compris
wider
varieti
function
properti
avail
publish
scientif
literatur
includ
level
detail
data
drug
toler
pk
efficaci
molecul
yet
enter
phase
clinic
test
howev
publish
abstract
scientif
meet
discuss
review
articl
provid
inform
transgen
mousederiv
mab
borchmann
et
al
heuck
et
al
boll
et
al
test
hodgkin
lymphoma
anaplast
larg
cell
lymphoma
patient
borchmann
et
al
klimm
et
al
fiftysix
patient
report
treat
mg
kg
everi
week
week
without
signific
infus
reaction
preliminari
result
interpret
indic
drug
well
toler
clinic
activ
preclin
result
also
publish
addit
transgenicderiv
mab
clinic
test
includ
antibodi
direct
villadsen
et
al
psma
holm
clostridium
difficil
toxin
b
babcock
et
al
tai
et
al
anthrax
protect
antigen
vital
et
al
hepatocyt
growth
factor
burgess
et
al
melanoma
antigen
glycoprotein
nmb
tse
et
al
insulinlik
growth
factor
receptor
cohen
et
al
v
integrin
trikha
et
al
martin
et
al
transgen
mice
express
human
antibodi
repertoir
proven
use
gener
highaffin
human
sequenc
mab
wide
varieti
potenti
drug
target
clinic
experi
varieti
transgen
mous
deriv
fulli
human
antibodi
human
patient
show
promis
efficaci
safeti
profil
sever
molecul
furthermor
overal
experi
date
technolog
succeed
deliv
human
mab
demonstr
rel
low
immunogen
rel
long
vivo
half
live
twelv
year
first
public
describ
transgen
mice
disrupt
endogen
immunoglobulin
loci
express
human
heavi
light
chain
repertoir
us
regulatori
approv
panitumumab
provid
commerci
valid
drug
discoveri
platform
addit
varieti
larg
number
differ
clinic
preclin
program
involv
human
mab
transgen
mice
suggest
technolog
continu
contribut
new
therapeut
drug
